Biolight resumed trading on August 10 and immediately hit its daily limit down, closing at 15.41 yuan per share, down 19.99 percent, with a total market value of 4.078 billion yuan. Before the suspension, the company had announced that its controlling shareholder was planning a major event that could lead to a change of control. However, on the evening of the 9th, it announced that due to the many issues involved, the relevant transaction parties decided to terminate the planning, and trading in the stock and convertible bonds resumed. The company stated that its operations are currently normal and that the termination will not have a material adverse impact on its performance or financial condition. Biolight has been suffering continuous losses in recent years, with net profit attributable to the parent company of minus 65.1851 million yuan, minus 71.4413 million yuan, and minus 69.4278 million yuan from 2023 to 2025, accumulating losses of over 200 million yuan over the three years.
Guangdong Biolight Meditech Co LtdControl change plan terminated, causing limit-down and uncertainty despite company stating operations normal.
